Associated Papers
Spotlight on amino acid changing mutations in the JAK-STAT pathway: from disease-specific mutation to general mutation databases.
Hoffmann M et al.
Scientific Reports, 2025
39979591 (PubMed )
Supplement: 41598_2025_90788_MOESM2_ESM.docx
PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.
Lahera A et al.
Npj Precision Oncology, 2024
39033228 (PubMed )
Supplement: 41698_2024_638_MOESM1_ESM.pdf
The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib.
Lahera A et al.
Molecular Carcinogenesis, 2024
JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
Bodaar K et al.
Leukemia, 2022
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
Abdel-Wahab R et al.
Scientific Reports, 2020
33328484 (PubMed )
Supplement: 41598_2020_77939_MOESM1_ESM.xlsx › Sheet1
Novel cavernous sinus TSC2/JAK3 mutant hemangioendothelioma in a teenager.
Sun S et al.
Bmj Case Reports, 2020
Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
Burns MA et al.
Leukemia, 2018
29654263 (PubMed )
Supplement: NIHMS944706-supplement-Table_S2.xlsx › Table_S2
Select a paper to view details